Returning guest Dr. Mike Clayman, CEO of Flexion, a biopharmaceutical company focusing on musculoskeletal conditions, talks about the preclinical studies on FX201, a locally administered gene therapy, that Flexion plans to initiate “first-in-human” clinical trials in 2019 for the treatment of OA of the knee.
Dr. Clayman is a co-founder of Flexion Therapeutics and has served as President, Chief Executive Officer and as one of the directors since inception in 2007. He also serves on the board of directors of Anokion SA and Kanyos Bio, both biopharmaceutical companies. Dr. Clayman served on the board of Akebia Therapeutics, a public biopharmaceutical company, from 2014 to 2018. Previously, he is the recipient of the Physician Scientist Award from the National Institutes of Health. He earned a B.A., cum laude, from Yale University and an M.D. from the University of California, San Diego School of Medicine. Following an internship and residency in Internal Medicine at the University of California, San Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research fellowships in Nephrology at the University of Pennsylvania.